Physician profile
Lorraine Stephens
NPI 1942382759
$2,492.27
in general payments reported to CMS, 2019-2025
22 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.26 · 2020: $125 · 2021: $191 · 2022: $143 · 2023: $440 · 2024: $938 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $343.10 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $313.97 | 2020-2025 | Farxiga, Flumist Quadrivalent |
| Abbvie INC. | $284.90 | 2024-2025 | |
| Pfizer INC. | $280.30 | 2024-2025 | |
| Glaxosmithkline, LLC. | $216.09 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $122.04 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.67 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $115.18 | 2021-2025 | Wegovy |
| Lucid Diagnostics INC. | $115.13 | 2023 | |
| Lilly USA, LLC | $102.10 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $87.01 | 2023-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.27 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $70.01 | 2023-2025 | |
| Amgen INC. | $61.76 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $46.13 | 2024-2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.08 | 2024 | Nexletol |
| Eisai INC. | $23.01 | 2025 | |
| Gilead Sciences, INC. | $22.44 | 2025 | |
| Dexcom, INC. | $18.67 | 2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.51 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $14.39 | 2021 | |
| Sanofi Pasteur INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.